Will Vidac Pharma continue its rally soon? There is a good chance that the biotech highflyer of the second half of 2024 has ended its consolidation. The Company aims to revolutionize cancer treatment and has attracted much attention within the biotech industry and the capital market with convincing research results. The success story is expected to continue in the current year. It is quite possible that a takeover could take place in 2025, as the takeover merry-go-round in the oncology sector has been turning fast since last year.
News & Events